|Bid||60.16 x 800|
|Ask||60.37 x 800|
|Day's Range||60.00 - 60.53|
|52 Week Range||31.46 - 70.50|
|Beta (3Y Monthly)||0.84|
|PE Ratio (TTM)||118.25|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.63|
WALTHAM, Mass., Feb. 15, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on.
Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RGEN totaled $1.18 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Mid-caps stocks, like Repligen Corporation (NASDAQ:RGEN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Repligen (RGEN) is a pure-play supplier of bioprocessing technologies. It is a market leader in proteins (over 95% market share), where it has a near monopoly, explains Tyler Laundon, editor of Cabot Small-Cap Confidential.
WALTHAM, Mass., Jan. 03, 2019 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will.
Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
The Dow Jones industrial average is leading another rebound on Wall Street following a sharp pullback in recent days. Chipotle, Attunity, Repligen and McDonald's are acting bullishly.
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
An underrated biotech, a boring industrials play, and an intriguing cloud company: Here's why these growth stocks deserve your attention.